Candel Therapeutics (CADL)
NASDAQ:CADL
Want to see CADL full AI Analyst Report?
Top Page
Candel Therapeutics
(NASDAQ:CADL)
Select Model
Select Model
Rating:59Neutral
Price Target:
$9.50
▲(49.14% Upside)
Action:Reiterated
Date:05/16/26
The score is held back primarily by weak financial performance (no revenue, sizable losses, and significant cash burn), partially offset by a stronger low-debt balance sheet. Technicals are supportive with a strong uptrend, but overbought signals raise near-term risk. Corporate updates are constructive (Phase 3 data and extended funding runway), while valuation signals remain unattractive due to negative earnings and no dividend.
Positive Factors
Positive Phase 3 Follow-up
Extended Phase 3 follow-up showing accumulating clinical benefit materially de-risks the lead program. Durable efficacy signals in a pivotal trial raise approval probability, improve the commercialization case, and strengthen negotiating leverage with partners and payors over the next several quarters.
Negative Factors
Pre-revenue with Large Losses
CADL remains pre-revenue with persistent, sizable net losses. The structural absence of product sales means the business depends on external funding and clinical milestones; continued losses increase dilution risk and constrain freedom to invest in parallel programs or extensive commercial rollout.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 3 Follow-up
Extended Phase 3 follow-up showing accumulating clinical benefit materially de-risks the lead program. Durable efficacy signals in a pivotal trial raise approval probability, improve the commercialization case, and strengthen negotiating leverage with partners and payors over the next several quarters.
Read all positive factors
Candel Therapeutics (CADL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$652.63M
Dividend YieldN/A
Average Volume (3M)1.26M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS Growth26.28%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.98
Shares Outstanding73,246,925
10 Day Avg. Volume1,336,622
30 Day Avg. Volume1,255,347
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-480.74
Enterprise Value/Ebitda-4.03
Forecast
1Y Price Target
$21.17Price Target Upside232.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.26
Revenue Forecast (FY)N/A
Candel Therapeutics Business Overview & Revenue Model
Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; ...
How the Company Makes Money
Candel Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it does not have approved products and therefore does not generate recurring product sales revenue. Its revenue, when present, is primarily...
Candel Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K |
| Gross Profit | -600.00K | -845.00K | -990.00K | -23.98M | 125.00K | -14.47M |
| EBITDA | -71.64M | -47.42M | -52.10M | -37.43M | -16.31M | -25.49M |
| Net Income | -54.42M | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M |
Balance Sheet | ||||||
| Total Assets | 201.92M | 125.19M | 106.87M | 41.20M | 78.52M | 89.20M |
| Cash, Cash Equivalents and Short-Term Investments | 194.83M | 119.73M | 102.65M | 35.41M | 70.06M | 82.64M |
| Total Debt | 1.80M | 1.90M | 13.47M | 22.76M | 22.80M | 560.00K |
| Total Liabilities | 63.89M | 73.27M | 40.54M | 28.46M | 30.80M | 25.07M |
| Stockholders Equity | 138.03M | 51.92M | 66.33M | 12.74M | 47.71M | 64.14M |
Cash Flow | ||||||
| Free Cash Flow | -48.99M | -38.90M | -27.04M | -34.70M | -32.72M | -24.05M |
| Operating Cash Flow | -47.73M | -38.31M | -27.02M | -34.24M | -31.42M | -22.22M |
| Investing Cash Flow | -1.23M | -560.00K | -16.00K | -280.00K | -1.30M | -1.83M |
| Financing Cash Flow | 151.78M | 56.10M | 94.28M | -121.00K | 19.97M | 71.80M |
Candel Therapeutics Technical Analysis
Positive
6.37
Price Trends
5.15
Positive
5.39
Positive
5.51
Positive
Market Momentum
0.10
Negative
75.36
Negative
91.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CADL, the sentiment is Positive. The current price of 6.37 is above the 20-day moving average (MA) of 5.00, above the 50-day MA of 5.15, and above the 200-day MA of 5.51, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 75.36 is Negative, neither overbought nor oversold. The STOCH value of 91.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CADL.
Candel Therapeutics Risk Analysis
Candel Therapeutics disclosed 91 risk factors in its most recent earnings report. Candel Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Candel Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $652.63M | -8.62 | -51.44% | ― | ― | 26.28% | |
55 Neutral | $1.58B | -6.06 | -40.99% | ― | -73.07% | -2335.85% | |
54 Neutral | $1.59B | -7.83 | -269.56% | ― | 550.00% | -107.04% | |
52 Neutral | $201.85M | -1.93 | -47.35% | ― | -46.21% | 23.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $206.50M | -1.70 | -424.76% | ― | 289.94% | 16.60% | |
48 Neutral | $250.91M | -1.17 | -60.15% | ― | 74.84% | 99.51% |
* Healthcare Sector Average
CADL
Candel Therapeutics
8.77
3.42
63.93%
TNXP
Tonix Pharma
15.74
-12.26
-43.79%
QSI
Quantum-Si
0.89
-0.59
-39.86%
HUMA
Humacyte
0.93
-1.31
-58.48%
GLUE
Monte Rosa Therapeutics
18.15
14.17
356.03%
INBX
Inhibrx Biosciences Inc
108.64
96.31
781.10%
Candel Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
Positive
May 15, 2026
On May 15, 2026, Candel Therapeutics held a live investor webcast in conjunction with the American Urological Association 2026 Annual Meeting to review extended follow-up data from its randomized, placebo-controlled phase 3 trial of aglatimagene b...
Business Operations and StrategyPrivate Placements and Financing
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
Positive
Feb 23, 2026
On February 19, 2026, Candel Therapeutics, Inc. entered into an underwriting agreement to sell 18,348,624 shares of common stock at $5.45 per share, with underwriters granted a 30-day option to buy up to an additional 2,752,293 shares. The registe...
Business Operations and StrategyPrivate Placements and Financing
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
Positive
Feb 19, 2026
On February 19, 2026, Candel Therapeutics announced a $100 million royalty-based funding agreement with funds managed by RTW Investments to support the potential U.S. launch of its lead candidate aglatimagene besadenovec for intermediate- to high-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.